The role of kidney injury biomarkers in COVID-19 |
| |
| Authors: | Lianjiu Su Jiahao Zhang Zhiyong Peng |
| |
| Affiliation: | aDepartment of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China;bDepartment of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA;cDepartment of Critical Care Medicine, Center of Critical Care Nephrology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA |
| |
| Abstract: | The coronavirus disease-2019 (COVID-19) outbreak has been declared a global pandemic. COVID-19-associated acute kidney injury (COVID-19 AKI) is related to a high mortality rate and serves as an independent risk factor for hospital death in patients with COVID-19. Early diagnosis would allow for earlier intervention and potentially improve patient outcomes. The goal of early identification of AKI has been the primary impetus for AKI biomarker research, and several kidney injury biomarkers have been demonstrated to be beneficial in predicting COVID-19 AKI as well as disease progression in COVID-19. Furthermore, such data provide valuable insights into the molecular mechanisms underlying this complex and unique disease and serve as a molecular phenotyping tool that could be utilized to direct clinical intervention. This review focuses on a number of kidney injury biomarkers, such as CysC, NAGAL, KIM-1, L-FABP, IL-18, suPAR, and [TIMP-2] • [IGFBP7], which have been widely studied in common clinical settings, such as sepsis, cardiac surgery, and contrast-induced AKI. We explore the role of kidney injury biomarkers in COVID-19 and discuss what remains to be learned. |
| |
| Keywords: | Acute kidney injury biomarker COVID-19 |
|
|
